BridgeBio ($BBIO) touted kidney-protective data for Attruby, differentiating it from ATTR-CM rivals
A posthoc analysis of BridgeBio's Attruby found sustained, placebo-adjusted improvements in kidney function markers through 30 months in patients with transthyretin amyloidosis cardiomyopathy, following an initial reversible dip in eGFR…
